Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy

Kamran Idrees, Joshua R. Edler, David C. Linehan, Steven M. Strasberg, David Jacques, Nicholas Hamilton, Ryan C. Fields, Dennis Lambert, Steven Kymes, William G. Hawkins

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives Pancreatic leak is a morbid complication following left pancreatectomy, which results in prolonged hospitalization, additional diagnostic testing and invasive procedures. The present authors have previously demonstrated that mesh reinforcement of stapled left pancreatectomy results in fewer pancreatic leaks. This study was conducted to investigate whether mesh reinforcement also results in cost benefits for the health care system. Methods A cost benefit model was developed to estimate net cost savings from the payer's perspective. The model is based on the results of a randomized, single-blinded trial of mesh versus no mesh reinforcement of the pancreatic remnant after left pancreatectomy. A two-way sensitivity analysis was conducted to determine the model's sensitivity to fluctuations in the cost of mesh and the effectiveness of the mesh in reducing clinically significant leaks. Results Average total costs for an episode of care were US$13 337 and US$15 505 for patients who did and did not receive mesh, respectively, which indicates savings of US$2168. Two-way sensitivity analysis showed that, given a probability of 1.9% for developing a clinically significant leak in patients in whom mesh reinforcement was used, the strategy would continue to save costs if mesh were priced at ≤US$1804. Conclusions Mesh reinforcement decreases clinically significant pancreatic leaks. Despite the additional cost of mesh reinforcement, the use of mesh reinforcement results in overall cost savings for the health care system because of the resultant decrease in the occurrence of clinically significant leaks.

Original languageEnglish (US)
Pages (from-to)893-898
Number of pages6
JournalHPB
Volume15
Issue number11
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Pancreatectomy
Cost-Benefit Analysis
Cost Savings
Costs and Cost Analysis
Episode of Care
Delivery of Health Care
Hospitalization

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Idrees, K., Edler, J. R., Linehan, D. C., Strasberg, S. M., Jacques, D., Hamilton, N., ... Hawkins, W. G. (2013). Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy. HPB, 15(11), 893-898. https://doi.org/10.1111/hpb.12055

Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy. / Idrees, Kamran; Edler, Joshua R.; Linehan, David C.; Strasberg, Steven M.; Jacques, David; Hamilton, Nicholas; Fields, Ryan C.; Lambert, Dennis; Kymes, Steven; Hawkins, William G.

In: HPB, Vol. 15, No. 11, 11.2013, p. 893-898.

Research output: Contribution to journalArticle

Idrees, K, Edler, JR, Linehan, DC, Strasberg, SM, Jacques, D, Hamilton, N, Fields, RC, Lambert, D, Kymes, S & Hawkins, WG 2013, 'Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy', HPB, vol. 15, no. 11, pp. 893-898. https://doi.org/10.1111/hpb.12055
Idrees K, Edler JR, Linehan DC, Strasberg SM, Jacques D, Hamilton N et al. Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy. HPB. 2013 Nov;15(11):893-898. https://doi.org/10.1111/hpb.12055
Idrees, Kamran ; Edler, Joshua R. ; Linehan, David C. ; Strasberg, Steven M. ; Jacques, David ; Hamilton, Nicholas ; Fields, Ryan C. ; Lambert, Dennis ; Kymes, Steven ; Hawkins, William G. / Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy. In: HPB. 2013 ; Vol. 15, No. 11. pp. 893-898.
@article{25afec5fd5b04f4eb54eb34caf20b913,
title = "Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy",
abstract = "Objectives Pancreatic leak is a morbid complication following left pancreatectomy, which results in prolonged hospitalization, additional diagnostic testing and invasive procedures. The present authors have previously demonstrated that mesh reinforcement of stapled left pancreatectomy results in fewer pancreatic leaks. This study was conducted to investigate whether mesh reinforcement also results in cost benefits for the health care system. Methods A cost benefit model was developed to estimate net cost savings from the payer's perspective. The model is based on the results of a randomized, single-blinded trial of mesh versus no mesh reinforcement of the pancreatic remnant after left pancreatectomy. A two-way sensitivity analysis was conducted to determine the model's sensitivity to fluctuations in the cost of mesh and the effectiveness of the mesh in reducing clinically significant leaks. Results Average total costs for an episode of care were US$13 337 and US$15 505 for patients who did and did not receive mesh, respectively, which indicates savings of US$2168. Two-way sensitivity analysis showed that, given a probability of 1.9{\%} for developing a clinically significant leak in patients in whom mesh reinforcement was used, the strategy would continue to save costs if mesh were priced at ≤US$1804. Conclusions Mesh reinforcement decreases clinically significant pancreatic leaks. Despite the additional cost of mesh reinforcement, the use of mesh reinforcement results in overall cost savings for the health care system because of the resultant decrease in the occurrence of clinically significant leaks.",
author = "Kamran Idrees and Edler, {Joshua R.} and Linehan, {David C.} and Strasberg, {Steven M.} and David Jacques and Nicholas Hamilton and Fields, {Ryan C.} and Dennis Lambert and Steven Kymes and Hawkins, {William G.}",
year = "2013",
month = "11",
doi = "10.1111/hpb.12055",
language = "English (US)",
volume = "15",
pages = "893--898",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Cost benefit analysis of mesh reinforcement of stapled left pancreatectomy

AU - Idrees, Kamran

AU - Edler, Joshua R.

AU - Linehan, David C.

AU - Strasberg, Steven M.

AU - Jacques, David

AU - Hamilton, Nicholas

AU - Fields, Ryan C.

AU - Lambert, Dennis

AU - Kymes, Steven

AU - Hawkins, William G.

PY - 2013/11

Y1 - 2013/11

N2 - Objectives Pancreatic leak is a morbid complication following left pancreatectomy, which results in prolonged hospitalization, additional diagnostic testing and invasive procedures. The present authors have previously demonstrated that mesh reinforcement of stapled left pancreatectomy results in fewer pancreatic leaks. This study was conducted to investigate whether mesh reinforcement also results in cost benefits for the health care system. Methods A cost benefit model was developed to estimate net cost savings from the payer's perspective. The model is based on the results of a randomized, single-blinded trial of mesh versus no mesh reinforcement of the pancreatic remnant after left pancreatectomy. A two-way sensitivity analysis was conducted to determine the model's sensitivity to fluctuations in the cost of mesh and the effectiveness of the mesh in reducing clinically significant leaks. Results Average total costs for an episode of care were US$13 337 and US$15 505 for patients who did and did not receive mesh, respectively, which indicates savings of US$2168. Two-way sensitivity analysis showed that, given a probability of 1.9% for developing a clinically significant leak in patients in whom mesh reinforcement was used, the strategy would continue to save costs if mesh were priced at ≤US$1804. Conclusions Mesh reinforcement decreases clinically significant pancreatic leaks. Despite the additional cost of mesh reinforcement, the use of mesh reinforcement results in overall cost savings for the health care system because of the resultant decrease in the occurrence of clinically significant leaks.

AB - Objectives Pancreatic leak is a morbid complication following left pancreatectomy, which results in prolonged hospitalization, additional diagnostic testing and invasive procedures. The present authors have previously demonstrated that mesh reinforcement of stapled left pancreatectomy results in fewer pancreatic leaks. This study was conducted to investigate whether mesh reinforcement also results in cost benefits for the health care system. Methods A cost benefit model was developed to estimate net cost savings from the payer's perspective. The model is based on the results of a randomized, single-blinded trial of mesh versus no mesh reinforcement of the pancreatic remnant after left pancreatectomy. A two-way sensitivity analysis was conducted to determine the model's sensitivity to fluctuations in the cost of mesh and the effectiveness of the mesh in reducing clinically significant leaks. Results Average total costs for an episode of care were US$13 337 and US$15 505 for patients who did and did not receive mesh, respectively, which indicates savings of US$2168. Two-way sensitivity analysis showed that, given a probability of 1.9% for developing a clinically significant leak in patients in whom mesh reinforcement was used, the strategy would continue to save costs if mesh were priced at ≤US$1804. Conclusions Mesh reinforcement decreases clinically significant pancreatic leaks. Despite the additional cost of mesh reinforcement, the use of mesh reinforcement results in overall cost savings for the health care system because of the resultant decrease in the occurrence of clinically significant leaks.

UR - http://www.scopus.com/inward/record.url?scp=84886086864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886086864&partnerID=8YFLogxK

U2 - 10.1111/hpb.12055

DO - 10.1111/hpb.12055

M3 - Article

VL - 15

SP - 893

EP - 898

JO - HPB

JF - HPB

SN - 1365-182X

IS - 11

ER -